Pfizer Stock News

Pfizer possesses several qualities that make it attractive when market volatility is high. The stock has a low forward earnings multiple and a higher -- yet still attractive -- EV-to-EBITDA ratio.

Income investors have been forced to seek yield in new places as stocks bump up against all-time highs. This diversified basket of blue chip names currently delivers over 7% annual yield.

The pharmaceutical powerhouse Johnson & Johnson (NYSE: JNJ) has significantly outperformed its competitor Pfizer (NYSE: PFE) this year. JNJ's stock has risen by almost 45%, whereas PFE has declined by 6%, greatly exceeding the S&P 500's 13% increase.

If you want to invest in top healthcare stocks, both of these are worth consideration. Pfizer is moving past the pandemic era, and tremendous growth could be ahead.

NEW YORK & TOKYO--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) today announced that the U.S. Food and Drug Administration (FDA) has approved PADCEV® (enfortumab vedotin-ejfv), a Nectin-4 directed antibody-drug conjugate (ADC), in combination with the PD-1 inhibitor Keytruda® (pembrolizumab) or Keytruda QLEX™ (pembrol...

Pfizer is pursuing a potentially lucrative area of the vast oncology market. The drugmaker is also targeting the fast-growing weight loss space.

In trading on Thursday, shares of Pfizer crossed below their 200 day moving average of $24.58, changing hands as low as $24.28 per share. Pfizer shares are currently trading off about 1.6% on the day.

Screening large-cap Health Care names using earnings yield plus ROTC identified five undervalued blue-chip stocks over $100B market cap. Merck, Bristol-Myers, Gilead, Pfizer, and Amgen screen as the cheapest quality names using a Magic-Formula-style scoring method.